Nitroxyl anion donor, Angeli's salt, does not develop tolerance in rat isolated aortae

Vasodilators are widely used in cardiovascular medicine, but many lose effectiveness over time due to tolerance. Traditional nitrovasodilators like glyceryl trinitrate (GTN) are known to develop tolerance in vascular tissues. This limitation reduces their long-term therapeutic value. Prior research has shown that nitric oxide (NO) activates guanylate cyclase to produce cGMP, a key mediator of smooth muscle relaxation. However, the role of nitroxyl (HNO) in vascular function is less understood. It was already known that HNO has distinct signaling pathways compared to NO. No prior work had resolved whether HNO donors could avoid tolerance development. This gap motivated researchers to compare HNO and NO donor responses in isolated rat aortae. The study aimed to determine if HNO donors like Angeli's salt (AS) could avoid tolerance issues seen with NO donors.

The study aimed to investigate whether HNO donors develop vascular tolerance in rat aortae. Traditional NO donors like GTN are known to induce tolerance, which limits their use in chronic conditions. The researchers hypothesized that HNO might avoid this limitation. They compared AS with GTN and DEA/NO to assess tolerance development. The motivation was to determine if HNO could offer a more stable therapeutic option. The study also sought to evaluate cross-tolerance between HNO and NO donors. By measuring vasorelaxation and cGMP accumulation, the team aimed to clarify the mechanisms of HNO action. The results could inform future drug development for cardiovascular diseases.

The study used isolated rat aortae to evaluate vasorelaxation responses to HNO and NO donors. Angeli's salt (AS), glyceryl trinitrate (GTN), and DEA/NO were tested for tolerance development. The experiments measured relaxation responses after pretreatment with each compound. Vasorelaxation was assessed using isometric tension measurements. cGMP accumulation was quantified to evaluate signaling pathways. The soluble guanylate cyclase inhibitor was used to differentiate between HNO and NO effects. Pretreatment concentrations of 10, 30, and 100 micromol/L were tested for 60 minutes. The study also examined cross-tolerance between HNO and NO donors using protein kinase G inhibitors.

Pretreatment with GTN significantly reduced its own vasorelaxation effect in a concentration-dependent manner. At 100 micromol/L, GTN caused a 48-fold decrease in sensitivity (P<0.01). In contrast, AS and DEA/NO pretreatment did not alter subsequent vasorelaxation responses. cGMP accumulation was highest with DEA/NO, followed by AS and then GTN. The soluble guanylate cyclase inhibitor reduced GTN responses more than AS or DEA/NO. Pre-exposure to DEA/NO caused a concentration-dependent attenuation of GTN-mediated relaxation. This effect was blocked by a protein kinase G inhibitor. AS pretreatment did not induce cross-tolerance to GTN. The time course of vasorelaxation and cGMP accumulation was similar across all three compounds.

The authors concluded that HNO donors like AS do not develop vascular tolerance in rat aortae. This contrasts with traditional NO donors like GTN, which show significant tolerance. The study also found no cross-tolerance between HNO and NO donors. These findings suggest that HNO donors may offer therapeutic advantages over current nitrovasodilators. The lack of tolerance development supports the potential use of HNO in long-term treatment. The distinct signaling pathways of HNO compared to NO may explain these differences. The study did not propose new mechanisms beyond those stated in the abstract. The results align with the hypothesis that HNO could provide more stable vasodilation effects.